Roles of cell signaling pathways in thyroid carcinoma

Abstract

Xu Yingkai, Hu Jie, Liu Wei. Roles of cell signaling pathways in thyroid carcinoma[J]. Journal of International Oncology, 2015, 42(12): 911-915.

［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］. CA Cancer J Clin, 2011, 61(2): 134. ［2］ Tuttle RM, Ball DW, Byrd D, et al. Thyroid carcinoma［J］. J Natl Compr Canc Netw, 2010, 8(11): 1228-1274. ［3］ Schneider DF, Chen H. New developments in the diagnosis and treatment of thyroid cancer［J］. CA Cancer J Clin, 2013, 63(6): 374-394. ［4］ Xing M. Molecular pathogenesis and mechanisms of thyroid cancer［J］. Nat Rev Cancer, 2013, 13(3): 184-199. ［5］ Omur O, Baran Y. An update on molecular biology of thyroid cancers［J］. Crit Rev Oncol Hematol, 2014, 90(3): 233-252. ［6］ Knauf JA, Fagin JA. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets［J］. Curr Opin Cell Biol, 2009, 21(2): 296-303. ［7］ Khan MS, Pandith AA, Azad N, et al. Impact of molecular alterations of BRAF in the pathogenesis of thyroid cancer［J］. Mutagenesis, 2014, 29(2): 131-137. ［8］ Charles RP, Silva J, Iezza G, et al. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis ［J］. Mol Cancer Res, 2014, 12(7): 979-986. ［9］ Watanabe R, Hayashi Y, Sassa M, et al. Possible involvement of BRAFV600E in altered gene expression in papillary thyroid cancer［J］. Endocr J, 2009, 56(3): 407-414. ［10］ Pasquali D, Santoro A, Bufo P, et al. Upregulation of endocrine glandderived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation［J］. Thyroid, 2011, 21(4): 391-399. ［11］ Zerilli M, Zito G, Martorana A, et al. BRAF(V600E) mutation influences hypoxiainducible factor 1αexpression levels in papillary thyroid cancer［J］. Mod Pathol, 2010, 23(8): 1052-1060. ［12］ Nucera C, Lawler J, Parangi S. BRAF (V600E) and thrombospondin1 promote thyroid cancer progression［J］. Cancer Res, 2011, 71(7): 2417-2422. ［13］ Knauf JA, Sartor MA, Medvedovic M, et al. Progression of BRAFinduced thyroid cancer is associated with epithelialmesenchymal transition requiring concomitant MAP kinase and TGFβ signaling［J］. Oncogene, 2011, 30(28): 3153-3162. ［14］ Khoury, Hu Q, Liu S, et al. Intarcystic papillary carcioma of breast: interrelationship with in situ and invasive carcinoma and a proposal of pathogenesis: array comparative genomic hybridization study of 14 cases［J］. Mod Pathol, 2014, 27(2): 194-203. ［15］ Tafani M, De Santis E, Coppola L, et al. Bridging hypoxia, inflammation and estrogen receptors in thyroid cancer progression［J］. Biomed Pharmacother, 2014, 68(1): 1-5. ［16］ Yamashita AS, Geraldo MV, Fuziwara CS, et al. Notch pathway is activated by MAPK signaling and influences papillary thyroid cancer prolifetration［J］. Transl Oncol, 2013, 6(2): 197-205. ［17］ ChocarroCalvo A, Zaballos MA, Santisteban P, et al. DARPP32 is required for MAPK/ERK signaling in thyroid cells［J］. Mol Endocrinol, 2012, 26(3): 471-480. ［18］ Karras S, Anagnostis P, Krassas GE. Vandetanib for the treatment of thyroid cancer: an update［J］. Expert Opin Drug Metab Toxical, 2014, 10(3): 469-481. ［19］ Gunda V, Bucur O, Varnau J, et al. Blocks to thyroid cancer cell apoptosis can be overcome by inhabitation of the MAPK and PI3K/AKT pathways［J］. Cell Death Dis, 2014, 5: e1104. ［20］ Xing M. Genetic alterations in the phosphatidylinositol 3 kinase/Akt pathway in thyroid cancer［J］. Thyroid, 2010, 20(7): 697-706. ［21］ de Biase D, Visani M, Pession A, et al. Molecular diagnosis of carcinomas of the thyroid gland［J］. Front Biosci, 2014, 6: 1-14. ［22］ Saji M, Ringel MD. The PI3K AktmTOR pathway in initiation and progression of thyroid tumors［J］. Mol Cell Endocrinol, 2010, 321(1): 20-28. ［23］ Legakis I, Syrigos K. Recent advances in molecular diagnosis of thyroid cancer［J］. J Thyroid Res, 2011, 2011: 384213. ［24］ Duman BB, Kara OI, Uˇguz A, et al. Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma［J］. Contemp Oncol (Pozn), 2014, 18(4): 234-240. ［25］ Hung CM, GarciaHaro L, Sparks CA, et al. mTORdependent cell survival mechanisms［J］. Cold Spring Harb Prespect Biol, 2012,4(12): pii a008771. ［26］ Larson SD, Silva SR, Rychahou PG, et al. PI3K/AKT activation is critical for early hepatic regeneration after partial hepatectomy［J］. Am J Physiol Gastrointest Liver Physiol, 2008, 294(6): 1401-1410. ［27］ Saji M, Narahara K, McCarty SK, et al. Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer［J］. Oncogene, 2011, 30(42): 4307-4315. ［28］ Parke RL, Bloch A, McGuinness SP. Effect of veryhighflow nasal therapy on airway pressure and endexpiratory lung impedance in healthy volunteers［J］. Respir Care, 2015, 60(10): 1397-1403. ［29］ Pacifico F, Leonardi A. Role of NFkappaB in thyroid cancer［J］. Mol Cell Endocrinol, 2010, 321(1): 29-35. ［30］ Parker M, Mohankumar KM, Punchihewa C, et al. C11orf95RELA fusions drive oncogenic NFκB signaling in ependymomac［J］. Nature, 2014, 506(7489): 451-455. ［31］ Zhang LL, Liu J, Lei S, et al. PTEN inhibits the invasion and metastasis of gastric cancer via downregulation of FAK expression［J］. Cell Signal, 2014, 26(5): 10111020. ［32］ Li X, AbdelMageed AB, Mondal D, et al. The nuclear factor kappaB signaling pathway as a therapeutic target against thyroid cancers［J］. Thyroid, 2013, 23(2): 209-218.

[1]	Zhang Jinnan, Liu Bangqing, Li Jun, Liu Xiaohui.Research on BHLHE40 targets HMGA2 to reduce the sensitivity of thyroid cancer cells to cisplatin through activating the oxidative phosphorylation pathway[J]. Journal of International Oncology, 2023, 50(7): 398-406.
[2]	Li Jinhao, Wang Guidong, Li Xuefei, Liu Zilin, Meng Kailong.Clinical study of venous phase CT value in predicting central group lymph node metastasis of papillary thyroid carcinoma[J]. Journal of International Oncology, 2022, 49(10): 581-585.
[3]	Wu Yuping, Zhang Xiaoyu, Lu Keyi.Mechanism of PD-L1 in thyroid carcinoma and its application in diagnosis and treatment[J]. Journal of International Oncology, 2021, 48(9): 560-563.
[4]	Feng Zhiping, Yang Chuanzhou, Chen Ting, Zhu Jialun, Liu Chao, Lyu Juan, Lu Jianmei, Deng Zhiyong.BRD4 inhibitor specifically inhibits the development of wild-type Kras differentiated thyroid carcinoma by regulating BRD4/miR-106b-5p/P21 axis[J]. Journal of International Oncology, 2021, 48(8): 463-472.
[5]	Hou Xiaofeng, Xue Jincai, Tian Youxin, Liu Qinjiang.Diagnosis and surgical treatment of differentiated thyroid carcinoma in 40 years[J]. Journal of International Oncology, 2020, 47(8): 449-456.
[6]	Cheng Hu, Liu Mingkui, Chen Tianping.Effects of lncRNA AFAP1-AS1 on proliferation and invasion of thyroid cancer cells and its mechanisms[J]. Journal of International Oncology, 2020, 47(6): 327-332.
[7]	Wang Jiale, Cao Jun.Progress of medical treatment for thyroid cancer[J]. Journal of International Oncology, 2020, 47(4): 231-235.
[8]	Zhang Lizhuo, Qian Yangyang, Zheng Guowan, Ge Minghua.Mechanism study of PD-1/PD-L1 in tumor and its value of diagnosis and treatment of thyroid cancer[J]. Journal of International Oncology, 2020, 47(1): 39-42.
[9]	Wu Yuanyuan, Wang Jun.Advancement of targeted agents in the treatment of anaplastic thyroid carcinoma[J]. Journal of International Oncology, 2019, 46(2): 98-101.
[10]	Dong Fang, Xue Jincai, Wang Yunsheng, Liu Qinjiang.Progress of external beam radiotherapy for thyroid cancer[J]. Journal of International Oncology, 2019, 46(11): 641-648.
[11]	Chen Hongcun, Li Liang, Jiang Ming, Zhang Jun, Yao Baozhong, Jiang You, Liao Lifang.Correlation analysis and clinical significance of lymph node metastasis in right recurrent laryngeal nerve of papillary thyroid carcinoma[J]. Journal of International Oncology, 2018, 45(7): 391-394.
[12]	Tan Xiangrong, Han Chun, Zhao Jiazheng, Guo Liang.Metastasis and dissection of lymph node posterior to right recurrent laryngeal nerve of papillary thyroid carcinoma[J]. Journal of International Oncology, 2018, 45(6): 365-367.
[13]	Li Yan, Chen Qiongxia, Wang Xuming.Effects of knockdown of Stat5 on invasion and epithelial mesenchymal transition of thyroid carcinoma TT cells[J]. Journal of International Oncology, 2018, 45(1): 1-.
[14]	Chen Lili, Lan Kuixu.RNA related markers of thyroid cancer[J]. Journal of International Oncology, 2017, 44(7): 534-536.
[15]	Wang Jiafeng, Ge Minghua..Analysis of risk factors of thyroid cancer[J]. Journal of International Oncology, 2017, 44(4): 284-286.

Roles of cell signaling pathways in thyroid carcinoma

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments